NEW YORK, March 13 (GenomeWeb News) - CombiMatrix Molecular Diagnostics, a subsidiary of Acacia Research's CombiMatrix group, said today that it has signed an agreement with Paris-based Array Genomics to co-develop and co-market a series of comparative genomic hybridization microarrays for diagnosing genetic anomalies associated with mental retardation.
CombiMatrix Molecular Diagnostics will manufacture the arrays in the
The arrays are expected to begin generating revenue for both companies "within the next several weeks," CMDX said in a statement.
The array-based CGH tests will reduce the time associated with the analysis of chromosomal imbalances compared to conventional cytogenetic approaches while increasing the detection resolution, CMDX said.
Matt Watson, CEO of CMDX, said in a statement that the company will also offer molecular diagnostic testing services based on CGH and gene expression profiling at its Irvine, Calif.-based clinical laboratory, and that it will also file "a number" of its tests with the US Food and Drug Administration for approval to market them within the US as in vitro diagnostics.